NV5 Awarded Contracts Totaling $11 Million for Energy Services
Mar 13, 2017 12:01 pm UTC| Business
HOLLYWOOD, Fla., March 13, 2017 -- NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq:NVEE), a provider of professional and technical engineering and consulting solutions, announced today that it was awarded dual...
Payment Data Systems Announces Intent to Acquire Singular Payments, LLC
Mar 13, 2017 12:01 pm UTC| Business
SAN ANTONIO, March 13, 2017 -- Payment Data Systems (NASDAQ:PYDS), an integrated electronic payment solutions provider, today announced that it has entered into a non-binding Letter of Intent to acquire Singular...
Payment Data Systems Announces Intent to Acquire Singular Payments, LLC
Mar 13, 2017 12:01 pm UTC| Business
SAN ANTONIO, March 13, 2017 -- Payment Data Systems (NASDAQ:PYDS), an integrated electronic payment solutions provider, today announced that it has entered into a non-binding Letter of Intent to acquire Singular...
Mar 13, 2017 12:01 pm UTC| Business
SAN DIEGO, March 13, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders,...
Mar 13, 2017 12:01 pm UTC| Business
SAN DIEGO, March 13, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders,...
Elite Pharmaceuticals, Inc. Initiates Pivotal Bioequivalence Fed Study for Reformulated SequestOx™
Mar 13, 2017 12:00 pm UTC| Business
NORTHVALE, N.J., March 13, 2017 -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced today that it has initiated pharmacokinetic testing of its reformulated SequestOx™. The reformulated...
Mar 13, 2017 12:00 pm UTC| Business
HOUSTON, March 13, 2017 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic...